Metabolic HealthFDA Approves First Oral GLP-1 Pill for Obesity and Once-Weekly Insulin for Diabetes
The FDA approved two landmark metabolic health drugs in early 2026. Foundayo (orforglipron) is the first oral small-molecule GLP-1 receptor agonist approved for long-term weight management in adults with obesity or overweight with a weight-related comorbidity, used alongside diet and exercise. Awiqli (insulin icodec-abae) is a once-weekly insulin approved to improve blood sugar control in adults with type 2 diabetes, potentially replacing daily basal insulin injections. These approvals represent a significant shift in how obesity and type 2 diabetes — two of the most consequential drivers of accelerated aging and reduced healthspan — can be managed, expanding access and adherence through more convenient dosing formats. Both conditions are strongly linked to cardiovascular disease, cognitive decline, and shortened lifespan.
